Novo Nordisk’s Wegovy Demonstrates Early Cardioprotective Effects in SELECT Trial
Danish pharmaceutical giant Novo Nordisk (NYSE: NVO, CPH: NOVO-B) announced groundbreaking secondary analysis results from...
CPH: NOVO-B
Novo Nordisk CEO Lars Fruergaard Jørgensen to Step Down Amid Market Challenges
Danish pharmaceutical giant Novo Nordisk (NYSE: NVO, CPH: NOVO-B) announced last week that Lars Fruergaard...
Novo Nordisk and Septerna Ink $2.2 Billion Deal for GPCR Drug Discovery
Denmark-based Novo Nordisk (NYSE: NVO, CPH: NOVO-B) and Septerna, Inc. (NASDAQ: SEPN) announced an exclusive...
Novo Nordisk Partners with PingAn Good Doctor to Promote Scientific Weight Loss in China
Denmark-based Novo Nordisk (NYSE: NVO, CPH: NOVO-B) has formed a strategic partnership with China’s Ping...
Novo Nordisk Reports 18% YOY Revenue Growth in Q1 2025
Denmark-based Novo Nordisk (NYSE: NVO, CPH: NOVO-B) released its Q1 2025 earnings report this week....
Novo Nordisk Reports Soaring Global Sales in 2024, Driven by Diabetes and Obesity Care
Denmark’s Novo Nordisk (CPH: NOVO-B) reported this week that its global sales during 2024 reached...
Novo Nordisk Secures Global Licensing Agreement with Ascendis Pharma for TransCon Technology
Denmark-based healthcare giant Novo Nordisk (NYSE: NVO; CPH: NOVO-B) has entered into a licensing agreement...
Novo Nordisk’s Semaglutide Meets Primary Endpoints in ESSENCE Phase III Study for MASH
Denmark-based pharmaceutical company Novo Nordisk (NYSE: NVO; CPH: Novo-B) has announced that part 1 of...
Novo Nordisk Faces US Senators’ Scrutiny Over Levemir Withdrawal
US senators, including Jeanne Shaheen, Raphael Warnock, and Elizabeth Warren, have voiced concerns over Novo...
Novo Nordisk Partners with Indonesia’s Bio Farma to Boost Asia-Pacific Diabetes Drug Production
Novo Nordisk (NYSE: NVO; CPH: NOVO-B), the Danish pharmaceutical giant specializing in diabetes care, is...
Novo Nordisk Plans Cautious Wegovy Launch in China to Preserve Global Supply
Novo Nordisk (NYSE: NVO; CPH: NOVO-B), a leading healthcare company, has reportedly planned a cautious...
Novo Nordisk’s Ocedurenone Misses Primary Endpoint in Chronic Kidney Disease Trial
Novo Nordisk (NYSE: NVO; CPH: NOVO-B), a Danish pharmaceutical company, has announced that its pipeline...
Novo Nordisk’s Semaglutide for Long-Term Weight Management Receives NMPA Approval
Novo Nordisk (NYSE: NVO, CPH: NOVO-B), a leading healthcare company from Denmark, has announced that...
Novo Holdings Gains Controlling Interest in Biopharma Equipment Supplier Single Use Support
Novo Nordisk’s (CPH: NOVO-B) controlling shareholder, Novo Holdings, has entered into an agreement to purchase...
Novo Nordisk’s Wegovy Shows Durable Weight Loss and Heart Health in Extended Trials
At the 31st European Congress on Obesity (ECO), Denmark’s pharmaceutical giant Novo Nordisk (CPH: NOVO-B)...
Novo Nordisk’s Bispecific Antibody Mim8 Achieves Milestone in Haemophilia A Trial
Novo Nordisk (CPH: NOVO-B), a pharmaceutical company based in Denmark, has announced that its bispecific...
Novo Nordisk’s Mim8 for Haemophilia A Exceeds Endpoints in Late-Stage Trial
Denmark-based healthcare company Novo Nordisk (CPH: NOVO-B) has announced positive results from a late-stage trial...
Novo Nordisk’s Q1 2024 Global Sales Surge 24% YOY on Strength of GLP-1 Therapies
Denmark-based pharmaceutical giant Novo Nordisk (CPH: NOVO-B) reported a substantial 24% year-on-year (YOY) increase in...
Novo Nordisk Acquires Cardior for €1.025 Billion to Strengthen Cardiovascular Portfolio
Denmark-based Novo Nordisk (CPH: NOVO-B) has announced a significant agreement to acquire Germany’s Cardior, a...